Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 1/20 | 0.94 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL6431587 | 1.00 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL42301 | 0.99 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL4051966 | 0.99 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL4594859 | 0.99 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL3855473 | 0.99 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2672138 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL3707643 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL16312 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2955 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL6053421 | 0.97 | SLC6A3 (0.92) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773811-B1 | A CRYSTALLINE VARIABLE HYDRATE OF (S)-6-(4-(2-((3-(9H-CARBAZOL-4-YLOXY)-2-HYDROXYPROPYL)AMINO)-2-METHYLPROPYL)PHENOXY)-3-PYRIDINECARBOX AMIDE HEMISUCCINATE SALT | LILLY CO ELI (US) | 2010-09-08 | — | — | EP | claimed |
| CN-1376061-A | Treatment of hiatial hernia | KNOLLPHARMACEUTICAL COMPANY (DE) | 2002-10-23 | — | — | CN | claimed |
| CN-1352552-A | Treatment of osteoarthritis | KNOLL PHARMACEUTICAL CO (DE) | 2002-06-05 | — | — | CN | claimed |
| EP-0282206-B1 | ARYLCYCLOBUTYLALKYLAMINE-DERIVATIVE FOR THE TREATMENT OF PARKINSON'S DISEASE | The Boots Company PLC (GB) | 1990-11-07 | — | — | EP | claimed |
| WO-2014054970-A1 | SOLID DOSAGE FORM HAVING AN ANORECTIC EFFECT (VARIANTS) | LOBKO VLADIMIR PAVLOVICH (RU) | 2014-04-10 | — | — | WO | disclosed |
| CN-1376061-A | Treatment of hiatial hernia | KNOLLPHARMACEUTICAL COMPANY (DE) | 2002-10-23 | — | — | CN | disclosed |
| CN-1352552-A | Treatment of osteoarthritis | KNOLL PHARMACEUTICAL CO (DE) | 2002-06-05 | — | — | CN | disclosed |